 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...1920212223242526272829...7475» |
- Avastin (bevacizumab) / Roche
Risk Factors of Poor Visual Outcomes Following Loss to Follow-Up Among Patients With Neovascular AMD Treated Under Universal Health Coverage (Morial Convention Center) - Oct 20, 2021 - Abstract #AAO2021AAO_1960;
Multivariate analysis showed that intraretinal fluid at the last visit before LTFU was a risk factor for poor visual outcomes (P = .034), and that presence of subretinal fluid (P = .04), and ranibizumab or aflibercept use (versus bevacizumab) (P = .022 and P = .006, respectively) were protective factors. Conclusion Our study identified multiple protective and risk factors of poor visual outcomes following a LTFU in nAMD patients.
- Lucentis (ranibizumab) / Roche, Novartis
Treatment Switch From Aflibercept to Ranibizumab in Canadian DME Patients in a Real-World Setting: The PRECISE Study (Morial Convention Center) - Oct 20, 2021 - Abstract #AAO2021AAO_1944;
There were no new safety findings. Conclusion Treatment switch from AFL to RBZ-PFS showed significant CRT reduction and improvement of visual acuity.
- Avastin (bevacizumab) / Roche
Intravitreal Injection Cost Saving of the Israeli Health Care System: A Retrospective Analysis of a Retina Clinic in a Tertiary Referral Center From 2016 to 2020 (Morial Convention Center) - Oct 20, 2021 - Abstract #AAO2021AAO_1940;
A change in treatment was needed in about a quarter of patients. Further analysis is required to assess the clinical outcomes of this strategy.
- Lucentis (ranibizumab) / Roche, Novartis
Impact of Race on Vision Outcomes in Ranibizumab-Treated Patients With DME (Morial Convention Center) - Oct 20, 2021 - Abstract #AAO2021AAO_1938;
P3
Conclusion Existing data are inconclusive regarding the impact of race on DME treatment outcomes. Increased enrollment of racial subgroups in clinical trials is critical.
- Lucentis (ranibizumab) / Roche, Novartis
Safety and Efficacy of a Ranibizumab Biosimilar Medication vs. Lucentis for Treatment of DME: A Randomized Clinical Trial (Morial Convention Center) - Oct 20, 2021 - Abstract #AAO2021AAO_1936;
No intraocular inflammation was observed in any of the eyes. Conclusion Vicentis was noninferior to Lucentis regarding VA and CSFT and caused no intraocular inflammation.
- faricimab (RG7716) / Roche
Exploring Ang2 Signaling in Vascular Stability in Patients With DME Receiving Faricimab in Phase 2 and Phase 3 Trials (Morial Convention Center) - Oct 20, 2021 - Abstract #AAO2021AAO_1713;
P2, P3
Conclusion FAR showed SRS and ICAM-1 reduction versus RBZ in Phase 2. In Phase 3, FAR showed greater anatomic improvement versus aflibercept and potential for improved durability due to VS by Ang-2 inhibition.
- Lucentis Port Delivery System (ranibizumab port delivery system) / Roche, Lucentis (ranibizumab) / Roche, Novartis
The Port Delivery System With Ranibizumab: A New Paradigm for Long-Acting Retinal Drug Delivery (Morial Convention Center; 255-257) - Oct 20, 2021 - Abstract #AAO2021AAO_1481;
P3
Conclusion The PDS continuously and reproducibly delivers RBZ over a period of months while maintaining potency. Archway Phase 3 trial (NCT03677934) results support the efficacy of the PDS.
- FYB201 (ranibizumab biosimilar) / Amneal, Formycon, Coherus, Teva, Lucentis (ranibizumab) / Roche, Novartis
Clinical Efficacy and Safety of Proposed Biosimilar FYB201 Compared to Reference Ranibizumab in Neovascular AMD (Morial Convention Center; HALL C) - Oct 20, 2021 - Abstract #AAO2021AAO_1157;
Adverse events and secondary endpoints were similar in both groups, with no clinically relevant differences. Conclusion FYB201 is similar to refRNB in terms of clinical efficacy and safety in treatment of patients with nAMD.
- Lucentis (ranibizumab) / Roche, Novartis
Clinical Features, Factors of Tumor Growth, Appearance of Tumor Vascular by SS-OCTA and Outcomes of Intravitreal Injection of VEGF Therapy in Patients With Choroidal Osteoma (Morial Convention Center; HALL C) - Oct 20, 2021 - Abstract #AAO2021AAO_1156;
Purpose To analyze the clinical characteristics of choroidal osteoma (CO) and tumor-related neovascularization using swept source optical coherence tomography angiography (SS-OCTA) and to evaluate tumor growth, tumor decalcification and the outcomes of intravitreal ranibizumab (IVR) injection therapy in patients with CO...Conclusion SS-OCTA can monitor and evaluate osteoma-related tumor blood vessels and growth status. Anti-VEGF therapy can control tumor growth.
- Avastin (bevacizumab) / Roche
Practice Patterns and Outcomes of Intravitreal Injections for ROP: A Multicenter Study (Morial Convention Center; HALL C) - Oct 20, 2021 - Abstract #AAO2021AAO_492;
Conclusion Anti-VEGF injections for ROP are safe with multiple practice patterns observed. Subsequent treatment may be required.
- | Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: The Evaluation of a Two-year Outcome of Intravitreal Conbercept versus Ranibizumab for Pathological Myopic Choroidal Neovascularization. (Pubmed Central) - Oct 20, 2021
Similar visual acuity and improved morphology were achieved in both groups. The two drugs were also found to be safe and effective in the treatment of pathological myopic CNV.
- | Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
New trial: Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome (clinicaltrials.gov) - Oct 17, 2021
P=N/A, N=450, Recruiting, Sponsor: European School of Advanced Studies in Ophthalmology
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy. (Pubmed Central) - Oct 15, 2021
A total of 42 eyes of 42 patients with treatment-naïve PNV who were treated with PDT combined with intravitreal injections of an anti-VEGF agent (ranibizumab or aflibercept) for 1 year...Of 20 eyes without polypoidal lesions, only 1 eye (5.0%) needed additional treatments. PNV, especially without polypoidal lesions, can be treated effectively with PDT combined with anti-VEGF therapy with few sessions.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Efficacy of Anti-Vascular Endothelial Growth Factor Treatment in Neovascular Age-Related Macular Degeneration and Systemic Cardiovascular Risk Factors. (Pubmed Central) - Oct 14, 2021
Patients received intravitreal injections of ranibizumab or aflibercept with the dosage and regimen set according to each manufacturer's recommendations for their product...Systemic arterial hypertension is an independent factor leading to a poor functional outcome following anti-VEGF therapy in patients with nAMD. Effects of anti-VEGF treatment in patients with high total cholesterol levels should be analyzed in further research.
- ||| Rayoqta (abicipar pegol) / Molecular Partners
Clinical, P3 data, Journal: Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration. (Pubmed Central) - Oct 14, 2021
First onset of IOI events with abicipar was much reduced in the second year and comparable to that with ranibizumab (0.8% and 2.3% vs 1.0%). The extended duration of effect of abicipar allows for quarterly dosing and reduced treatment burden.
- | Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: Comparative Risk of Arterial Thromboembolic Events Between Aflibercept and Ranibizumab in Patients with Maculopathy: A Population-Based Retrospective Cohort Study. (Pubmed Central) - Oct 14, 2021
There was no difference in mortality risk between the two groups. Our study could provide strong grounds for future prospective studies to confirm the findings.
- | Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: Comparison of the Effect of Intravitreal Conbercept and Ranibizumab on Aqueous Humor Cytokines in Central Retinal Vein Occlusion-Related Macular Edema. (Pubmed Central) - Oct 13, 2021
Our study could provide strong grounds for future prospective studies to confirm the findings. IVC and IVR induced comparable improvements in clinical parameters, along with equivalent reductions in the concentrations of angiogenic and inflammatory cytokines in the aqueous humor.
- || Zaltrap intravitreal (ziv-aflibercept intravitreal) / Regeneron, Sanofi, Avastin (bevacizumab) / Roche
Clinical, Journal: Ziv-aflibercept for Better Regulating Neovascular Age-Related Macular Degeneration (ZEBRA): A Prospective, Randomized Trial. (Pubmed Central) - Oct 10, 2021
Ziv-aflibercept is a safe and effective as a maintenance drug for patients with nAMD. It may represent a cost-effective alternative to aflibercept and second-line therapy for eye resistant bevacizumab or ranibizumab.
- | Lucentis (ranibizumab) / Roche, Novartis
Retrospective data, Journal: Reduced Expression of Erythropoietin After Intravitreal Ranibizumab in Proliferative Diabetic Retinopathy Patients-Retrospective Interventional Study. (Pubmed Central) - Oct 9, 2021
Both of the VEGF and EPO level were significantly increased in PDR patients, which have equal diagnostic value in the prediction of PDR. IVR could reduce the EPO level, but not enough to the normal level.
- | Avastin (bevacizumab) / Roche
Journal: Anti-VEGF Treatment in Corneal Diseases. (Pubmed Central) - Oct 9, 2021
IVR could reduce the EPO level, but not enough to the normal level. The efficacy and safety of anti-VEGF agents support their adoption into the daily clinical practice for the management of CN.
- | Avastin (bevacizumab) / Roche
Journal: Use Of Anti-Vegf Drugs In Retinal Vein Occlusions. (Pubmed Central) - Oct 9, 2021
Antivascular endothelial growth factor (anti-VEGF) injections have demonstrated better results than other previous options including observation or laser therapy. This narrative review aims to analyze the current aspects related to these drugs.
- || Avastin (bevacizumab) / Roche
Review, Journal: Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration. (Pubmed Central) - Oct 8, 2021
Newer and future anti-VEGF therapies aim to decrease injection frequency through eitherlonger half life or port-delivery systems (brolucizumab, conbercept, KSI-301, ranibizumab). This review outlines current anti-VEGF treatments and ways by which their duration might be extended.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Galectin-3 Enhances Vascular Endothelial Growth Factor-A Receptor 2 Activity in the Presence of Vascular Endothelial Growth Factor. (Pubmed Central) - Oct 8, 2021
Gal3 depletion led to no reduction in VEGF-induced cell function. Since Gal3 has been suggested to be a potential therapeutic target for VEGFR2-mediated angiogenesis, it is crucial to define the possible Gal3-mediated VEGFR2 signal transduction mechanism to aid the development of efficacious therapeutic strategies.
- | levosulpiride / Generic mfg.
Trial primary completion date: Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema (clinicaltrials.gov) - Oct 4, 2021
P2, N=120, Recruiting, Sponsor: Carmen Clapp
Since Gal3 has been suggested to be a potential therapeutic target for VEGFR2-mediated angiogenesis, it is crucial to define the possible Gal3-mediated VEGFR2 signal transduction mechanism to aid the development of efficacious therapeutic strategies. Trial primary completion date: May 2022 --> Sep 2022
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron
Review, Journal: Pipeline therapies for neovascular age related macular degeneration. (Pubmed Central) - Oct 3, 2021
Those in the pipeline of VEGF targets include abicipar pegol (Abicipar; Allergan, Coolock, Dublin), OPT-302 (Opthea; OPTHEA limited; Victoria, Melbourne), conbercept (Lumitin; Chengdu Kanghong Pharmaceutical Group, Chengdu, Sichuan), and KSI-301 (Kodiak Sciences, Palo Alto, CA)...Gene therapy present possible longer treatments options as well and are reviewed here. This paper will highlight the past approved medications as well as pipeline therapies for neovascular AMD.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Differences in the characteristics of subjects achieving complete, partial, or no resolution of macular edema in the READ-3 study. (Pubmed Central) - Oct 2, 2021
This paper will highlight the past approved medications as well as pipeline therapies for neovascular AMD. Subjects with high CST (> 570 μm) at baseline may not benefit from repeated intravitreal injections of anti-VEGF for resolution of edema.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: 2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial. (Pubmed Central) - Oct 2, 2021
P3
2-year outcomes following ranibizumab 0·2 mg for the treatment of ROP confirm the ocular outcomes of the original RAINBOW trial and show reduced high myopia, with possibly better vision-related quality of life. This treatment did not appear to affect non-ocular infant development.
- | Avastin (bevacizumab) / Roche
Observational data, Retrospective data, Journal: Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data. (Pubmed Central) - Oct 1, 2021
Current intravitreal anti-VEGF treatment and monitoring requirements place considerable economic burden on the French healthcare system. New intravitreal therapies with extended dosing intervals and predictable efficacy might reduce demand on ophthalmology services.
- || Triesence (triamcinolone acetonide injectable suspension) / Novartis, Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration. (Pubmed Central) - Sep 29, 2021
It is worth noting that the average number of RBZ injections was significantly lower in the RBZ-TALF group (2.5 ± 1.4 vs. 6.1 ± 1.3 IVTs; p = 0.0004). Therefore, TALF used as an adjuvant to RBZ reduces the need for RBZ-IVT retreatment with optimal visual and anatomic results.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal, HEOR: The Effect of Ranibizumab Loading Treatment on Vision-Related Quality of Life in Diabetic Macular Edema. (Pubmed Central) - Sep 26, 2021
Interestingly, a significant improvement in quality of life was observed even though the patients could see well with the fellow eye. In conclusion, the NEI VFQ-25 TR is a useful scale to evaluate the changes in visual function and psychosocial characteristics of DME patients after treatment.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Observational data, Journal: Application of machine learning methods to bridge the gap between non-interventional studies and randomized controlled trials in ophthalmic patients with neovascular age-related macular degeneration. (Pubmed Central) - Sep 26, 2021
Machine learning techniques can be used to classify real world cohorts and identify subsets of patients who benefit to the same extent as that reported in RCTs. This methodology may support the translation of clinical trial findings to treatment performance in the clinical practice setting.
- | Avastin (bevacizumab) / Roche
Journal: Thirteen years of intravitreal anti-vascular endothelial growth factor therapy: the promises and burdens of a paradigm shift told from the perspective of the largest retina service in Norway. (Pubmed Central) - Sep 25, 2021
Macular degeneration was the most common diagnosis. Using bevacizumab as first-line treatment, with aflibercept reserved for resistant cases from 2013, eventually resulted in a nearly 1:1 ratio in drug usage.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Intravitreal ranibizumab for persistent diabetic vitreous haemorrhage: a randomised, double-masked, placebo-controlled feasibility study. (Pubmed Central) - Sep 25, 2021
Intravitreal ranibizumab may reduce the likelihood of proceeding to vitrectomy in patients with persistent, dense diabetic vitreous haemorrhage. Further studies appear feasible and justified.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Clinical data, Journal: Different Outcomes of Anti-VEGF Treatment for Neovascular AMD according to Neovascular Sutypes and Baseline Features: 2-Year Real-Life Clinical Outcomes. (Pubmed Central) - Sep 24, 2021
Anti-VEGF approach is generally effective in stopping nAMD progression in our real-life analysis. No difference was found comparing patients treated with ranibizumab and aflibercept, nor in patients with drug switching.
- || Avastin (bevacizumab) / Roche
Clinical, Journal, HEOR: Economic burden of age-related macular degeneration in routine clinical practice: the RAMDEBURS study. (Pubmed Central) - Sep 23, 2021
AMD was associated with considerable healthcare costs for regional healthcare systems. Diagnostic examinations, particularly OCT examinations, and anti-VEGF treatment represented the largest cost items.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Comparison of Intravitreal Dexamethasone Implant and Ranibizumab in Vitrectomized Eyes with Diabetic Macular Edema. (Pubmed Central) - Sep 21, 2021
We concluded that IDI and IVR can both effectively treat vitrectomized eyes with DME. Dexamethasone implants had significantly better visual/anatomical improvement, smaller treatment number, and higher rate of elevated IOP after injection than IVR in pseudophakic vitrectomized eyes with DME in a 6-month period.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: External Limiting Membrane Disruption Predicts Long-Term Outcome in Strict Treat-And-Extend Regimen in Neovascular Age-Related Macular Degeneration. (Pubmed Central) - Sep 21, 2021
In this retrospective study we followed treatment-naïve subjects with nAMD starting treatment with either ranibizumab or aflibercept in a TER without loading dose but with predefined exit criteria for up to 8 years...Significant visual gains were sustained in a long-term TER in a real-world setting. Integrity of ELM at baseline predicted BCVA gain at 5 years and the potential for TER exit due to success.
- | Axpaxli (intravitreal axitinib implant) / Ocular Therap
Trial completion date, Trial primary completion date: CLN-0046: Treatment of AMD Subjects With OTX-TKI (clinicaltrials.gov) - Sep 21, 2021
P1, N=26, Recruiting, Sponsor: Ocular Therapeutix, Inc.
Integrity of ELM at baseline predicted BCVA gain at 5 years and the potential for TER exit due to success. Trial completion date: Nov 2021 --> Dec 2022 | Trial primary completion date: Nov 2021 --> Dec 2022
- ||| Byooviz (ranibizumab biosimilar) / Samsung, AffaMed Therap, Biogen, Lucentis (ranibizumab) / Roche, Novartis
FDA event: $BIIB FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna) https://t.co/o43hDT3YnE (Twitter) - Sep 20, 2021
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Beyond the Visual Acuity: Assessing the Visual Function in mCNV Patients After Anti-VEGF Treatment. (Pubmed Central) - Sep 18, 2021
Integral lifting in several aspects of visual function was observed in mCNV after ranibizumab treatment. Macular integrity and metamorphopsia, but not visual acuity, were associated with VR-QoL.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Retrospective data, Journal, Combination therapy: Long-term prognosis of polypoidal choroidal vasculopathy with a 5-year remission after an initial combination therapy. (Pubmed Central) - Sep 17, 2021
The combination therapy showed a favourable outcome for PCV over a 7-year follow-up, especially in the eyes without recurrence during the 1-5 year. Physicians should be careful of recurrent exudation in the eyes without recurrence during the 1-5 years, although the recurrence rate was low.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: THE CORRELATION BETWEEN AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AND CLINICAL ACTIVITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. (Pubmed Central) - Sep 16, 2021
Pretreatment aqueous VEGF level was significantly correlated with the likelihood of recurrence in neovascular age-related macular degeneration. The measurement of pretreatment aqueous VEGF level may be useful to determine the best treatment options for patients with neovascular age-related macular degeneration.
- | Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
Journal: RANIBIZUMAB WITH OR WITHOUT VERTEPORFIN PHOTODYNAMIC THERAPY FOR POLYPOIDAL CHOROIDAL VASCULOPATHY: Predictors of Visual and Anatomical Response in the EVEREST II Study. (Pubmed Central) - Sep 16, 2021
Several imaging parameters at baseline and M3 can predict treatment outcome. The interaction between treatment arm and total polypoidal lesion area suggests this feature may assist selecting between initial ranibizumab monotherapy or combination therapy.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Predicting the immediate impact of national lockdown on neovascular age-related macular degeneration and associated visual morbidity: an INSIGHT Health Data Research Hub for Eye Health report. (Pubmed Central) - Sep 15, 2021
P3
Here, we demonstrate how combining data from a recently founded national digital health data repository with historical industry-funded clinical trial data can enhance predictive modelling in nAMD. The demonstrated detrimental effects of prolonged treatment delay should incentivise healthcare providers to support nAMD patients accessing care in safe environments.
- ||| Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
There once was a drug called Avastin But Lucentis brought so much more cash in Genentech wouldn’t run a DMD trial So they could stay in denial That both drugs had effects that were lastin’ (Twitter) - Sep 14, 2021
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Retrospective data, Journal: Activation of quiescent polypoidal choroidal vasculopathy after membrane peeling vitrectomy for epiretinal membrane: a case report. (Pubmed Central) - Sep 8, 2021
Careful evaluation for PCV before membrane peeling vitrectomy for ERM is important, as indolent PCV may be activated postoperatively. Anti-VEGF therapy accompanied by laser photocoagulation may be more effective for PCV polyps located away from the fovea.
- | Lucentis (ranibizumab) / Roche, Novartis
Journal: Anti-VEGF Therapy Reduces Inflammation in Diabetic Macular Edema. (Pubmed Central) - Sep 8, 2021
These findings suggest that IRI reduces subclinical inflammation and that the aqueous flare value is influenced by inflammatory factors/cytokines. In addition, the change in the aqueous flare value may be an indicator of the response of CMT to IRI in patients with DME.
- | Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Biotech
Journal: The role of serum inflammation-based factors in Anti-VEGF treatment for macular edema secondary to retinal vein occlusion and its subtypes. (Pubmed Central) - Sep 8, 2021
Higher pretreatment PLR was associated with BCVA in patients with RVO-ME and its subtypes who were treated with anti-VEGF drugs. The PLR may be used as a predictive and prognostic tool for effective intravitreal injection treatment outcomes.
- | Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron
Preclinical, Journal: Efficacy of Aflibercept Treatment and its Effect on the Retinal Perfusion in the Oxygen-Induced Retinopathy Mouse Model of Retinopathy of Prematurity. (Pubmed Central) - Sep 8, 2021
The study shows that the area of non-perfused retina decreases effectively with aflibercept at PN25 with 100 ng dosage. With the 1,000 ng dosage, there is an inhibition of the physiologic angiogenesis with a higher area of non-perfused retina.
- || Lucentis (ranibizumab) / Roche, Novartis
Clinical, Journal: Changes in the Systemic Expression of Sirtuin-1 and Oxidative Stress after Intravitreal Anti-Vascular Endothelial Growth Factor in Patients with Retinal Vein Occlusion. (Pubmed Central) - Sep 8, 2021
Our study showed that the systemic oxidative stress increased in RVO patients. The aVEGF therapy could alter the gene expression of anti-oxidative proteins and reduce systemic oxidative stress in these patients.